img

Global and United States Biosimilars Drug Market Report & Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Biosimilars Drug Market Report & Forecast 2024-2034

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Market Analysis and InsightsGlobal and United States Biosimilars Drug Market
This report focuses on global and United States Biosimilars Drug market, also covers the segmentation data of other regions in regional level and county level.
The global Biosimilars Drug revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the review period (2024-2034).
In United States the Biosimilars Drug revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period 2024-2034.
The global key players of Biosimilars Drug include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, etc. The global five biggest players hold a share of % in 2024.
Global Biosimilars Drug Scope and Market Size
Biosimilars Drug market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Biosimilars Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2034.
For United States market, this report focuses on the Biosimilars Drug market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.



By Company


Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Celltrion
Pfizer
Novartis
Dr Reddy’s
Celgen Biopharma
Eli Lilly
Sanofi
Geropharm
Biocon
Wockhardt
Segment by Type
Monoclonal Antibodies
Insulin
Others

Segment by Application


Hospital
Retail Pharmacy
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Biosimilars Drug definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Biosimilars Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Biosimilars Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilars Drug revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions

Table of Content

1 Study Coverage
1.1 Biosimilars Drug Product Introduction
1.2 Global Biosimilars Drug Outlook 2018 VS 2024 VS 2034
1.2.1 Global Biosimilars Drug Market Size for the Year 2018-2034
1.2.2 United States Biosimilars Drug Market Size for the Year 2018-2034
1.3 Biosimilars Drug Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.3.1 The Market Share of United States Biosimilars Drug in Global, 2018 VS 2024 VS 2034
1.3.2 The Growth Rate of Biosimilars Drug Market Size, United States VS Global, 2018 VS 2024 VS 2034
1.4 Biosimilars Drug Market Dynamics
1.4.1 Biosimilars Drug Industry Trends
1.4.2 Biosimilars Drug Market Drivers
1.4.3 Biosimilars Drug Market Challenges
1.4.4 Biosimilars Drug Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Biosimilars Drug by Type
2.1 Biosimilars Drug Market Segment by Type
2.1.1 Monoclonal Antibodies
2.1.2 Insulin
2.1.3 Others
2.2 Global Biosimilars Drug Market Size by Type (2018, 2024 & 2034)
2.3 Global Biosimilars Drug Market Size by Type (2018-2034)
2.4 United States Biosimilars Drug Market Size by Type (2018, 2024 & 2034)
2.5 United States Biosimilars Drug Market Size by Type (2018-2034)
3 Biosimilars Drug by Application
3.1 Biosimilars Drug Market Segment by Application
3.1.1 Hospital
3.1.2 Retail Pharmacy
3.1.3 Other
3.2 Global Biosimilars Drug Market Size by Application (2018, 2024 & 2034)
3.3 Global Biosimilars Drug Market Size by Application (2018-2034)
3.4 United States Biosimilars Drug Market Size by Application (2018, 2024 & 2034)
3.5 United States Biosimilars Drug Market Size by Application (2018-2034)
4 Global Biosimilars Drug Competitor Landscape by Company
4.1 Global Biosimilars Drug Market Size by Company
4.1.1 Global Key Companies of Biosimilars Drug, Ranked by Revenue (2024)
4.1.2 Global Biosimilars Drug Revenue by Player (2018-2023)
4.2 Global Biosimilars Drug Concentration Ratio (CR)
4.2.1 Biosimilars Drug Market Concentration Ratio (CR) (2018-2023)
4.2.2 Global Top 5 and Top 10 Largest Companies of Biosimilars Drug in 2024
4.2.3 Global Biosimilars Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Biosimilars Drug Head office and Area Served
4.4 Global Key Players of Biosimilars Drug, Product and Application
4.5 Global Key Players of Biosimilars Drug, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 United States Biosimilars Drug Market Size by Company
4.7.1 Key Players of Biosimilars Drug in United States, Ranked by Revenue (2024)
4.7.2 United States Biosimilars Drug Revenue by Players (2021, 2024 & 2023)
5 Global Biosimilars Drug Market Size by Region
5.1 Global Biosimilars Drug Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Biosimilars Drug Market Size by Region (2018-2034)
5.2.1 Global Biosimilars Drug Market Size by Region: 2018-2023
5.2.2 Global Biosimilars Drug Market Size by Region (2024-2034)
6 Americas
6.1 Americas Biosimilars Drug Market Size YoY Growth 2018-2034
6.2 Americas Biosimilars Drug Market Size by Type
6.2.1 Americas Biosimilars Drug Market Size by Type (2018-2023)
6.2.2 Americas Biosimilars Drug Market Size by Type (2024-2034)
6.2.3 Americas Biosimilars Drug Market Share by Type (2018-2034)
6.3 Americas Biosimilars Drug Market Size by Application
6.3.1 Americas Biosimilars Drug Market Size by Application (2018-2023)
6.3.2 Americas Biosimilars Drug Market Size by Application (2024-2034)
6.3.3 Americas Biosimilars Drug Market Share by Application (2018-2034)
6.4 Americas Biosimilars Drug Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Biosimilars Drug Market Size YoY Growth 2018-2034
7.2 EMEA Biosimilars Drug Market Size by Type
7.2.1 EMEA Biosimilars Drug Market Size by Type (2018-2023)
7.2.2 EMEA Biosimilars Drug Market Size by Type (2024-2034)
7.2.3 EMEA Biosimilars Drug Market Share by Type (2018-2034)
7.3 EMEA Biosimilars Drug Market Size by Application
7.3.1 EMEA Biosimilars Drug Market Size by Application (2018-2023)
7.3.2 EMEA Biosimilars Drug Market Size by Application (2024-2034)
7.3.3 EMEA Biosimilars Drug Market Share by Application (2018-2034)
7.4 EMEA Biosimilars Drug Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Biosimilars Drug Market Size YoY Growth 2018-2034
8.2 China Biosimilars Drug Market Size by Type
8.2.1 China Biosimilars Drug Market Size by Type (2018-2023)
8.2.2 China Biosimilars Drug Market Size by Type (2024-2034)
8.2.3 China Biosimilars Drug Market Share by Type (2018-2034)
8.3 China Biosimilars Drug Market Size by Application
8.3.1 China Biosimilars Drug Market Size by Application (2018-2023)
8.3.2 China Biosimilars Drug Market Size by Application (2024-2034)
8.3.3 China Biosimilars Drug Market Share by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Biosimilars Drug Market Size YoY Growth 2018-2034
9.2 APAC Biosimilars Drug Market Size by Type
9.2.1 APAC Biosimilars Drug Market Size by Type (2018-2023)
9.2.2 APAC Biosimilars Drug Market Size by Type (2024-2034)
9.2.3 APAC Biosimilars Drug Market Share by Type (2018-2034)
9.3 APAC Biosimilars Drug Market Size by Application
9.3.1 APAC Biosimilars Drug Market Size by Application (2018-2023)
9.3.2 APAC Biosimilars Drug Market Size by Application (2024-2034)
9.3.3 APAC Biosimilars Drug Market Share by Application (2018-2034)
9.4 APAC Biosimilars Drug Market Facts & Figures by Country (2018, 2024 & 2034)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 Qilu Pharmaceutical
10.1.1 Qilu Pharmaceutical Company Details
10.1.2 Qilu Pharmaceutical Business Overview
10.1.3 Qilu Pharmaceutical Biosimilars Drug Introduction
10.1.4 Qilu Pharmaceutical Revenue in Biosimilars Drug Business (2018-2023)
10.1.5 Qilu Pharmaceutical Recent Development
10.2 Bio-Thera
10.2.1 Bio-Thera Company Details
10.2.2 Bio-Thera Business Overview
10.2.3 Bio-Thera Biosimilars Drug Introduction
10.2.4 Bio-Thera Revenue in Biosimilars Drug Business (2018-2023)
10.2.5 Bio-Thera Recent Development
10.3 Zhejiang Hisun
10.3.1 Zhejiang Hisun Company Details
10.3.2 Zhejiang Hisun Business Overview
10.3.3 Zhejiang Hisun Biosimilars Drug Introduction
10.3.4 Zhejiang Hisun Revenue in Biosimilars Drug Business (2018-2023)
10.3.5 Zhejiang Hisun Recent Development
10.4 Shanghai Henlius
10.4.1 Shanghai Henlius Company Details
10.4.2 Shanghai Henlius Business Overview
10.4.3 Shanghai Henlius Biosimilars Drug Introduction
10.4.4 Shanghai Henlius Revenue in Biosimilars Drug Business (2018-2023)
10.4.5 Shanghai Henlius Recent Development
10.5 Innovent Biologics
10.5.1 Innovent Biologics Company Details
10.5.2 Innovent Biologics Business Overview
10.5.3 Innovent Biologics Biosimilars Drug Introduction
10.5.4 Innovent Biologics Revenue in Biosimilars Drug Business (2018-2023)
10.5.5 Innovent Biologics Recent Development
10.6 Jiangsu Hengrui
10.6.1 Jiangsu Hengrui Company Details
10.6.2 Jiangsu Hengrui Business Overview
10.6.3 Jiangsu Hengrui Biosimilars Drug Introduction
10.6.4 Jiangsu Hengrui Revenue in Biosimilars Drug Business (2018-2023)
10.6.5 Jiangsu Hengrui Recent Development
10.7 Gan&Lee
10.7.1 Gan&Lee Company Details
10.7.2 Gan&Lee Business Overview
10.7.3 Gan&Lee Biosimilars Drug Introduction
10.7.4 Gan&Lee Revenue in Biosimilars Drug Business (2018-2023)
10.7.5 Gan&Lee Recent Development
10.8 Tonghua Dongbao
10.8.1 Tonghua Dongbao Company Details
10.8.2 Tonghua Dongbao Business Overview
10.8.3 Tonghua Dongbao Biosimilars Drug Introduction
10.8.4 Tonghua Dongbao Revenue in Biosimilars Drug Business (2018-2023)
10.8.5 Tonghua Dongbao Recent Development
10.9 United Laboratory
10.9.1 United Laboratory Company Details
10.9.2 United Laboratory Business Overview
10.9.3 United Laboratory Biosimilars Drug Introduction
10.9.4 United Laboratory Revenue in Biosimilars Drug Business (2018-2023)
10.9.5 United Laboratory Recent Development
10.10 3SBIO
10.10.1 3SBIO Company Details
10.10.2 3SBIO Business Overview
10.10.3 3SBIO Biosimilars Drug Introduction
10.10.4 3SBIO Revenue in Biosimilars Drug Business (2018-2023)
10.10.5 3SBIO Recent Development
10.11 Luye Pharma
10.11.1 Luye Pharma Company Details
10.11.2 Luye Pharma Business Overview
10.11.3 Luye Pharma Biosimilars Drug Introduction
10.11.4 Luye Pharma Revenue in Biosimilars Drug Business (2018-2023)
10.11.5 Luye Pharma Recent Development
10.12 Celltrion
10.12.1 Celltrion Company Details
10.12.2 Celltrion Business Overview
10.12.3 Celltrion Biosimilars Drug Introduction
10.12.4 Celltrion Revenue in Biosimilars Drug Business (2018-2023)
10.12.5 Celltrion Recent Development
10.13 Pfizer
10.13.1 Pfizer Company Details
10.13.2 Pfizer Business Overview
10.13.3 Pfizer Biosimilars Drug Introduction
10.13.4 Pfizer Revenue in Biosimilars Drug Business (2018-2023)
10.13.5 Pfizer Recent Development
10.14 Novartis
10.14.1 Novartis Company Details
10.14.2 Novartis Business Overview
10.14.3 Novartis Biosimilars Drug Introduction
10.14.4 Novartis Revenue in Biosimilars Drug Business (2018-2023)
10.14.5 Novartis Recent Development
10.15 Dr Reddy’s
10.15.1 Dr Reddy’s Company Details
10.15.2 Dr Reddy’s Business Overview
10.15.3 Dr Reddy’s Biosimilars Drug Introduction
10.15.4 Dr Reddy’s Revenue in Biosimilars Drug Business (2018-2023)
10.15.5 Dr Reddy’s Recent Development
10.16 Celgen Biopharma
10.16.1 Celgen Biopharma Company Details
10.16.2 Celgen Biopharma Business Overview
10.16.3 Celgen Biopharma Biosimilars Drug Introduction
10.16.4 Celgen Biopharma Revenue in Biosimilars Drug Business (2018-2023)
10.16.5 Celgen Biopharma Recent Development
10.17 Eli Lilly
10.17.1 Eli Lilly Company Details
10.17.2 Eli Lilly Business Overview
10.17.3 Eli Lilly Biosimilars Drug Introduction
10.17.4 Eli Lilly Revenue in Biosimilars Drug Business (2018-2023)
10.17.5 Eli Lilly Recent Development
10.18 Sanofi
10.18.1 Sanofi Company Details
10.18.2 Sanofi Business Overview
10.18.3 Sanofi Biosimilars Drug Introduction
10.18.4 Sanofi Revenue in Biosimilars Drug Business (2018-2023)
10.18.5 Sanofi Recent Development
10.19 Geropharm
10.19.1 Geropharm Company Details
10.19.2 Geropharm Business Overview
10.19.3 Geropharm Biosimilars Drug Introduction
10.19.4 Geropharm Revenue in Biosimilars Drug Business (2018-2023)
10.19.5 Geropharm Recent Development
10.20 Biocon
10.20.1 Biocon Company Details
10.20.2 Biocon Business Overview
10.20.3 Biocon Biosimilars Drug Introduction
10.20.4 Biocon Revenue in Biosimilars Drug Business (2018-2023)
10.20.5 Biocon Recent Development
10.21 Wockhardt
10.21.1 Wockhardt Company Details
10.21.2 Wockhardt Business Overview
10.21.3 Wockhardt Biosimilars Drug Introduction
10.21.4 Wockhardt Revenue in Biosimilars Drug Business (2018-2023)
10.21.5 Wockhardt Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details

List of Figure

List of Tables
Table 1. Biosimilars Drug Market Size United States VS Global, CAGR (2018 VS 2024 VS 2034)
Table 2. Biosimilars Drug Market Trends
Table 3. Biosimilars Drug Market Drivers
Table 4. Biosimilars Drug Market Challenges
Table 5. Biosimilars Drug Market Restraints
Table 6. Global Biosimilars Drug Market Size by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. United States Biosimilars Drug Market Size by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Biosimilars Drug Market Size by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. United States Biosimilars Drug Market Size by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Companies of Biosimilars Drug, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Biosimilars Drug Revenue by Player, (US$ Million), 2018-2023
Table 12. Global Biosimilars Drug Revenue Share by Player, 2018-2023
Table 13. Global Biosimilars Drug Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilars Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Drug as of 2024)
Table 15. Global Key Players of Biosimilars Drug, Headquarters and Area Served
Table 16. Global Key Players of Biosimilars Drug, Product and Application
Table 17. Global Key Players of Biosimilars Drug, Date of Enter into This Industry
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Key Players of Biosimilars Drug in United States, Ranked by Revenue (2024) & (US$ Million)
Table 20. United States Biosimilars Drug Revenue by Players, (US$ Million), 2021, 2024 & 2023
Table 21. United States Biosimilars Drug Revenue Share by Players, 2021, 2024 & 2023
Table 22. Global Biosimilars Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 23. Global Biosimilars Drug Market Size by Region (2018-2023) & (US$ Million)
Table 24. Global Biosimilars Drug Market Size Forecast by Region (2024-2034) & (US$ Million)
Table 25. Americas Biosimilars Drug Market Size by Type (2018-2023) & (US$ Million)
Table 26. Americas Biosimilars Drug Market Size by Type (2024-2034) & (US$ Million)
Table 27. Americas Biosimilars Drug Market Size by Application (2018-2023) & (US$ Million)
Table 28. Americas Biosimilars Drug Market Size by Application (2024-2034) & (US$ Million)
Table 29. Americas Biosimilars Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 30. Americas Biosimilars Drug Market Size by Country (2018-2023) & (US$ Million)
Table 31. Americas Biosimilars Drug Market Size by Country (2024-2034) & (US$ Million)
Table 32. EMEA Biosimilars Drug Market Size by Type (2018-2023) & (US$ Million)
Table 33. EMEA Biosimilars Drug Market Size by Type (2024-2034) & (US$ Million)
Table 34. EMEA Biosimilars Drug Market Size by Application (2018-2023) & (US$ Million)
Table 35. EMEA Biosimilars Drug Market Size by Application (2024-2034) & (US$ Million)
Table 36. EMEA Biosimilars Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 37. EMEA Biosimilars Drug Market Size by Country (2018-2023) & (US$ Million)
Table 38. EMEA Biosimilars Drug Market Size by Country (2024-2034) & (US$ Million)
Table 39. China Biosimilars Drug Market Size by Type (2018-2023) & (US$ Million)
Table 40. China Biosimilars Drug Market Size by Type (2024-2034) & (US$ Million)
Table 41. China Biosimilars Drug Market Size by Application (2018-2023) & (US$ Million)
Table 42. China Biosimilars Drug Market Size by Application (2024-2034) & (US$ Million)
Table 43. China Biosimilars Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 44. APAC Biosimilars Drug Market Size by Type (2018-2023) & (US$ Million)
Table 45. APAC Biosimilars Drug Market Size by Type (2024-2034) & (US$ Million)
Table 46. APAC Biosimilars Drug Market Size by Application (2018-2023) & (US$ Million)
Table 47. APAC Biosimilars Drug Market Size by Application (2024-2034) & (US$ Million)
Table 48. APAC Biosimilars Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 49. APAC Biosimilars Drug Market Size by Region (2018-2023) & (US$ Million)
Table 50. APAC Biosimilars Drug Market Size by Region (2024-2034) & (US$ Million)
Table 51. Qilu Pharmaceutical Company Details
Table 52. Qilu Pharmaceutical Business Overview
Table 53. Qilu Pharmaceutical Biosimilars Drug Product
Table 54. Qilu Pharmaceutical Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 55. Qilu Pharmaceutical Recent Development
Table 56. Bio-Thera Company Details
Table 57. Bio-Thera Business Overview
Table 58. Bio-Thera Biosimilars Drug Product
Table 59. Bio-Thera Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 60. Bio-Thera Recent Development
Table 61. Zhejiang Hisun Company Details
Table 62. Zhejiang Hisun Business Overview
Table 63. Zhejiang Hisun Biosimilars Drug Product
Table 64. Zhejiang Hisun Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 65. Zhejiang Hisun Recent Development
Table 66. Shanghai Henlius Company Details
Table 67. Shanghai Henlius Business Overview
Table 68. Shanghai Henlius Biosimilars Drug Product
Table 69. Shanghai Henlius Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 70. Shanghai Henlius Recent Development
Table 71. Innovent Biologics Company Details
Table 72. Innovent Biologics Business Overview
Table 73. Innovent Biologics Biosimilars Drug Product
Table 74. Innovent Biologics Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 75. Innovent Biologics Recent Development
Table 76. Jiangsu Hengrui Company Details
Table 77. Jiangsu Hengrui Business Overview
Table 78. Jiangsu Hengrui Biosimilars Drug Product
Table 79. Jiangsu Hengrui Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 80. Jiangsu Hengrui Recent Development
Table 81. Gan&Lee Company Details
Table 82. Gan&Lee Business Overview
Table 83. Gan&Lee Biosimilars Drug Product
Table 84. Gan&Lee Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 85. Gan&Lee Recent Development
Table 86. Tonghua Dongbao Company Details
Table 87. Tonghua Dongbao Business Overview
Table 88. Tonghua Dongbao Biosimilars Drug Product
Table 89. Tonghua Dongbao Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 90. Tonghua Dongbao Recent Development
Table 91. United Laboratory Company Details
Table 92. United Laboratory Business Overview
Table 93. United Laboratory Biosimilars Drug Product
Table 94. United Laboratory Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 95. United Laboratory Recent Development
Table 96. 3SBIO Company Details
Table 97. 3SBIO Business Overview
Table 98. 3SBIO Biosimilars Drug Product
Table 99. 3SBIO Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 100. 3SBIO Recent Development
Table 101. Luye Pharma Company Details
Table 102. Luye Pharma Business Overview
Table 103. Luye Pharma Biosimilars Drug Product
Table 104. Luye Pharma Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 105. Luye Pharma Recent Development
Table 106. Celltrion Company Details
Table 107. Celltrion Business Overview
Table 108. Celltrion Biosimilars Drug Product
Table 109. Celltrion Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 110. Celltrion Recent Development
Table 111. Pfizer Company Details
Table 112. Pfizer Business Overview
Table 113. Pfizer Biosimilars Drug Product
Table 114. Pfizer Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 115. Pfizer Recent Development
Table 116. Novartis Company Details
Table 117. Novartis Business Overview
Table 118. Novartis Biosimilars Drug Product
Table 119. Novartis Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 120. Novartis Recent Development
Table 121. Dr Reddy’s Company Details
Table 122. Dr Reddy’s Business Overview
Table 123. Dr Reddy’s Biosimilars Drug Product
Table 124. Dr Reddy’s Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 125. Dr Reddy’s Recent Development
Table 126. Celgen Biopharma Company Details
Table 127. Celgen Biopharma Business Overview
Table 128. Celgen Biopharma Biosimilars Drug Product
Table 129. Celgen Biopharma Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 130. Celgen Biopharma Recent Development
Table 131. Eli Lilly Company Details
Table 132. Eli Lilly Business Overview
Table 133. Eli Lilly Biosimilars Drug Product
Table 134. Eli Lilly Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 135. Eli Lilly Recent Development
Table 136. Sanofi Company Details
Table 137. Sanofi Business Overview
Table 138. Sanofi Biosimilars Drug Product
Table 139. Sanofi Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 140. Sanofi Recent Development
Table 141. Geropharm Company Details
Table 142. Geropharm Business Overview
Table 143. Geropharm Biosimilars Drug Product
Table 144. Geropharm Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 145. Geropharm Recent Development
Table 146. Biocon Company Details
Table 147. Biocon Business Overview
Table 148. Biocon Biosimilars Drug Product
Table 149. Biocon Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 150. Biocon Recent Development
Table 151. Wockhardt Company Details
Table 152. Wockhardt Business Overview
Table 153. Wockhardt Biosimilars Drug Product
Table 154. Wockhardt Revenue in Biosimilars Drug Business (2018-2023) & (US$ Million)
Table 155. Wockhardt Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilars Drug Product Picture
Figure 2. Global Biosimilars Drug Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Biosimilars Drug Market Size 2018-2034 (US$ Million)
Figure 4. United States Biosimilars Drug Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 5. United States Biosimilars Drug Market Size 2018-2034 (US$ Million)
Figure 6. United States Biosimilars Drug Market Share in Global 2018-2034
Figure 7. Biosimilars Drug Report Years Considered
Figure 8. Product Picture of Monoclonal Antibodies
Figure 9. Product Picture of Insulin
Figure 10. Product Picture of Others
Figure 11. Global Biosimilars Drug Market Share by Type in 2024 & 2034
Figure 12. Global Biosimilars Drug Market Size by Type (2018-2034) & (US$ Million)
Figure 13. Global Biosimilars Drug Market Share by Type (2018-2034)
Figure 14. United States Biosimilars Drug Market Share by Type in 2024 & 2034
Figure 15. United States Biosimilars Drug Market Size by Type (2018-2034) & (US$ Million)
Figure 16. United States Biosimilars Drug Market Share by Type (2018-2034)
Figure 17. Product Picture of Hospital
Figure 18. Product Picture of Retail Pharmacy
Figure 19. Product Picture of Other
Figure 20. Global Biosimilars Drug Market Share by Application in 2024 & 2034
Figure 21. Global Biosimilars Drug Market Size by Application (2018-2034) & (US$ Million)
Figure 22. Global Biosimilars Drug Market Share by Application (2018-2034)
Figure 23. United States Biosimilars Drug Market Share by Application in 2024 & 2034
Figure 24. United States Biosimilars Drug Market Size by Application (2018-2034) & (US$ Million)
Figure 25. United States Biosimilars Drug Market Share by Application (2018-2034)
Figure 26. The Top 5 and 10 Largest Companies of Biosimilars Drug in the World: Market Share by Biosimilars Drug Revenue in 2024
Figure 27. Global Biosimilars Drug Market Size Market Share by Region: 2018 VS 2024 VS 2034
Figure 28. Global Biosimilars Drug Market Share by Region (2018-2034)
Figure 29. Americas Biosimilars Drug Market Size Growth Rate 2018-2034 (US$ Million)
Figure 30. Americas Biosimilars Drug Market Share by Type (2018-2034)
Figure 31. Americas Biosimilars Drug Market Share by Application (2018-2034)
Figure 32. United States Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 33. Canada Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 34. Mexico Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 35. Brazil Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 36. EMEA Biosimilars Drug Market Size Growth Rate 2018-2034 (US$ Million)
Figure 37. EMEA Biosimilars Drug Market Share by Type (2018-2034)
Figure 38. EMEA Biosimilars Drug Market Share by Application (2018-2034)
Figure 39. Europe Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 40. Middle East Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 41. Africa Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 42. China Biosimilars Drug Market Size Growth Rate 2018-2034 (US$ Million)
Figure 43. China Biosimilars Drug Market Share by Type (2018-2034)
Figure 44. China Biosimilars Drug Market Share by Application (2018-2034)
Figure 45. APAC Biosimilars Drug Market Size Growth Rate 2018-2034 (US$ Million)
Figure 46. APAC Biosimilars Drug Market Share by Type (2018-2034)
Figure 47. APAC Biosimilars Drug Market Share by Application (2018-2034)
Figure 48. Japan Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 49. South Korea Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 50. China Taiwan Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 51. Southeast Asia Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 52. India Biosimilars Drug Market Size Growth Rate (2018-2034) & (US$ Million)
Figure 53. Qilu Pharmaceutical Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 54. Bio-Thera Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 55. Zhejiang Hisun Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 56. Shanghai Henlius Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 57. Innovent Biologics Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 58. Jiangsu Hengrui Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 59. Gan&Lee Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 60. Tonghua Dongbao Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 61. United Laboratory Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 62. 3SBIO Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 63. Luye Pharma Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 64. Celltrion Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 65. Pfizer Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 66. Novartis Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 67. Dr Reddy’s Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 68. Celgen Biopharma Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 69. Eli Lilly Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 70. Sanofi Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 71. Geropharm Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 72. Biocon Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 73. Wockhardt Revenue Growth Rate in Biosimilars Drug Business (2018-2023)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries